Comparative Efficacy of Pharmacological Treatments for Adults With Autosomal Dominant Polycystic Kidney Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

• Váldodahkkit: Shunichiro Tsukamoto (Dahkki), Shingo Urate (Dahkki), Takayuki Yamada (Dahkki), Kengo Azushima (Dahkki), Takahiro Yamaji (Dahkki), Sho Kinguchi (Dahkki), Kazushi Uneda (Dahkki), Tomohiko Kanaoka (Dahkki), Hiromichi Wakui (Dahkki), Kouichi Tamura (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Frontiers Media S.A., 2022-05-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Background: Tolvaptan is the gold standard treatment for autosomal dominant polycystic kidney disease (ADPKD), while several other drugs have the potential to inhibit the progression of ADPKD. However, individual clinical trials may not show sufficient differences in clinical efficacy due to small s...